-
-
-
-
-
-
-
FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date
-
-
-
-
-
-
-
Omeros Corporation Reports Second Quarter 2021 Financial Results
-
-
-
-
-
-
-
Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results
-
-
-
-
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

